id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2014-D-1167-0024,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2022-12-22T05:00:00Z,2022,12,,,2022-12-22T13:50:27Z,2022-27827,0,0,090000648554d546
FDA-2014-D-1167-0025,FDA,FDA-2014-D-1167,Controlled Correspondence Related to Generic Drug Development; Guidance for Industry; Draft Guidance,Other,Guidance,2022-12-22T05:00:00Z,2022,12,2022-12-22T05:00:00Z,2023-02-22T04:59:59Z,2024-03-18T13:33:56Z,,0,0,090000648554cff7